FDA Approves Clinical Trial Application for SYH2059
SYH2095 tablets, a Class 1 chemical new drug co-developed by the Group and Hangzhou Innogate Pharma Co., Ltd., has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The Product is a novel, highly selective lysine acetyltransferase 6 (‘‘KAT6’’) inhibitor and belongs to a class of epigenetic anticancer drugs. The Product exerts its anti-tumor effects by inhibiting the acetylation of histone lysine, blocking open chromatin, and thereby regulating the cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors.
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month